Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.53 |
| ▸ | AHR | P35869 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
| ▸ | RARB | P10826 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.47 |
| ▸ | CHRNA10 | Q9GZZ6 | 2/20 | 0.47 |
| ▸ | CHRNA9 | Q9UGM1 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9997145 | 1.00 | NR5A1 (0.53) | NR5A1AHRTP53TSHRPLA2G4B | |
| SCHEMBL9997954 | 1.00 | NR5A1 (0.53) | NR5A1AHRTP53TSHRPLA2G4B | |
| SCHEMBL3432332 | 1.00 | NR5A1 (0.53) | NR5A1AHRTP53TSHRPLA2G4B | |
| SCHEMBL9997950 | 1.00 | NR5A1 (0.53) | NR5A1AHRTP53TSHRPLA2G4B | |
| SCHEMBL9997765 | 1.00 | NR5A1 (0.53) | NR5A1AHRTP53TSHRPLA2G4B | |
| SCHEMBL9997219 | 1.00 | NR5A1 (0.53) | NR5A1AHRTP53TSHRPLA2G4B | |
| SCHEMBL9997763 | 1.00 | NR5A1 (0.53) | NR5A1AHRTP53TSHRPLA2G4B | |
| SCHEMBL9618743 | 1.00 | NR5A1 (0.53) | NR5A1AHRTP53TSHRPLA2G4B | |
| SCHEMBL7278717 | 1.00 | NR5A1 (0.53) | NR5A1AHRTP53TSHRPLA2G4B | |
| SCHEMBL7369341 | 0.98 | AHR (0.54) | NR5A1AHRTP53TSHRPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838621-B1 | COMPOSITE OXIDES OR HYDOXIDES COMPRISING ALUMINA, ZIRCONIA AND OPTIONALLY CERIA AND/OR RARE EARTH OXIDES FOR AUTOMOTIVE CATALYST APPLICATIONS AND METHOD OF MANUFACTURING | MAGNESIUM ELEKTRON LTD (GB) | 2011-12-28 | — | — | EP | claimed |
| JP-4368343-A | — | — | None | — | — | JP | disclosed |
| US-8558012-B2 | 2-fluoro-1,3-benzodithiol 1,1,3,3-tetraoxide derivative, production method thereof, and production method of monofluoromethyl group-containing compound using the same | NAGOYA INSTITUTE OF TECHNOLOGY (JP) | 2013-10-15 | — | — | US | disclosed |
| US-20110319637-A1 | 2-FLUORO-1,3-BENZODITHIOL 1,1,3,3-TETRAOXIDE DERIVATIVE, PRODUCTION METHOD THEREOF, AND PRODUCTION METHOD OF MONOFLUOROMETHYL GROUP-CONTAINING COMPOUND USING THE SAME | NAGOYA INSTITUTE OF TECHNOLOGY (JP) | 2011-12-29 | — | — | US | disclosed |
| JP-H04368343-A | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE USING THE COMPOSITION | HITACHI LTD | 1992-12-21 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319637-A1 | 2-FLUORO-1,3-BENZODITHIOL 1,1,3,3-TETRAOXIDE DERIVATIVE, PRODUCTION METHOD THEREOF, AND PRODUCTION METHOD OF MONOFLUOROMETHYL GROUP-CONTAINING COMPOUND USING THE SAME | CBR1, CYP1B1, CYP2F1 | NR5A1 1149/4885AHR 1267/4885TP53 4307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.